By Timothy L. O’Brien | Bloomberg,
Subscribe to Crash Course on the iHeartRadio appSubscribe to Crash Course on Apple Podcasts Subscribe to Crash Course on Spotify
This is the second episode of a new Bloomberg Opinion podcast, Crash Course, about business, political and social disruption — and what we can learn from those collisions. This installment focuses on a handful of extraordinarily innovative pharmaceutical and biotechnology companies that developed Covid-19 vaccines in record time during a daunting global pandemic — and then butted heads in a race to secure riches. Moderna Inc., one of those miracle workers, offers a case study in the ups and downs of disruption. Join your host, Tim O’Brien, and his guest today, Dr. Monica Gandhi, as they discuss all of this. Gandhi is a leading virologist and epidemiologist who teaches at the University of California, San Francisco. She’s also the author of a new book, “Endemic: A Post-Pandemic Playbook,” which will be published this summer. Have a listen:
This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.
Timothy L. O’Brien is senior executive editor of Bloomberg Opinion. A former editor and reporter for the New York Times, he is author of “TrumpNation: The Art of Being the Donald.”
More stories like this are available on bloomberg.com/opinion
©2023 Bloomberg L.P.